Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?

Cancer treatment and research communications - 1 Jan 2021

Rizzo Alessandro, Ricci Angela Dalia, Brandi Giovanni

Abstract excerpt

Cholangiocarcinomas (CCAs) are a heterogenous group of hepatobiliary tumors with poor prognosis and limited therapeutic options. In the last decade, the advent of genomic profiling has led to the identification of several putative actionable aberrations in CCAs, and genomic characterization is playing an increasing role in the management of these malignancies. Thus, a wide number of targetable mutations are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Cholangiocarcinoma
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Glycine

Share to Isocitrate Dehydrogenase

Share to Pyridines

Share to Quinolines

Source

Identifiers

PMID: 33799004
DOI: 10.1016/j.ctarc.2021.100356

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?PMID 33799004Read ↗

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Semantic proximity Read ↗

Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.Semantic proximity Read ↗

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To DateSemantic proximity Read ↗

Ivosidenib: A Review in Advanced Cholangiocarcinoma.Semantic proximity Read ↗

IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future PerspectivesSemantic proximity Read ↗

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis.Semantic proximity Read ↗

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future TherapiesSemantic proximity Read ↗

IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic TargetingSemantic proximity Read ↗

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.Semantic proximity Read ↗

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Semantic proximity Read ↗

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma cells to MDM2 inhibitorsSemantic proximity Read ↗

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.